PhRMA, BIO Mum On Trump’s Tariffs
Executive Summary
While pressing the US trade representative for stronger IP protection, groups representing the brand biopharma sector remain silent on the Trump administration’s plan to hit China with 25% tariffs.
Topics
- Subjects
- Manufacturing
- Trade Policy
- Regions
- North America
- Asia Pacific
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS123151
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS123151
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.